Transplantation Therapies
Embodiments of the present invention are directed to methods and dosage forms for treating inflammation and rejection in transplantation injuries with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.
1 - 42 . (canceled)
43 . A dosage form for treating transplantation injury comprising an effective amount of Bryostatin-1, Bryostatin-1 analog or a pharmaceutically acceptable salt thereof to reduce or prevent induced neutrophil trans endothelial migration wherein said dosage form is a sterile, isotonically acceptable and pH acceptable, nontoxic aqueous solution for perfusion to a transplantation organ for administration to a human or animal in need thereof; wherein said dosage form comprises saturated polyalkylene glycol glyceride.
44 . The dosage form of claim 43 wherein said polyalkylene glycol glyceride is a mixture of polyalkylene esters of one or more eight carbons to eighteen carbons saturated fatty acids with glycerol.
45 . The dosage form of claim 44 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1000 to 2000 daltons.
46 . The dosage form of claim 46 wherein said polyalkylene glycol is a polyethylene glycol having a molecular eight of 1400 to 1600 daltons.
47 . The dosage form of claim 43 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical formulation in an amount of 0.00005 to 0.5% by weight.
48 . The dosage form of claim 43 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical formulation in an amount of 0.001 to 0.1% by weight.
49 . The dosage form of claim 43 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical parenteral formulation as a dispersion in water having a concentration of 0.01 to 0.1% by weight.
50 . The dosage form of claim 43 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical parenteral formulation as a dispersion in water having a concentration of 0.0005 to 0.5% by weight.
51 . The dosage form of claim 43 wherein said effective amount is a plasma concentration is about 10 −7 M.